-
D9134-1G
2 3-DIPHOSPHO-D-GLYCERIC ACID PENTA(CYCLOHEXYLAMMONIUM) SALT >=97% (TLC) (C005B-053986)
Price: $1,798.20List Price: $1,998.00Application D-Glycerate 2,3-diphosphate (DPG), cofactor of both phosphoglyceric acid mutase and hemoglobin, may be used as a reference compound in analysis of blood cell (erythrocyte) glycolysic cycle metabolites. 2,3-diphosphoglycerate (DPG) may -
18120-1
6-Prostaglandin I1-1 mg (C003B-223986)
Price: $185.86List Price: $206.516&beta-PGI1 is a stable PGI2 analog resistant to hydrolysis in aqueous solutions. 6&beta-PGI1 has a much longer half-life than PGI2, but a greatly reduced molar potency for receptor mediated function. -
786-820
ACD (Acid Citrate Dextrose) Solution A (38mM citric acid, 107mM sodium citrate, 136mM dextrose), 100mL
Price: $398.50List Price: $442.78ACD (Acid Citrate Dextrose) Solution A andACD (Acid Citrate Dextrose)Solution B are anticoagulants for whole blood and also act as acidifying agents to platelet poor plasma. Features Solution A: 38mM citric acid, 107mM sodium citrate, 136mM dextrose -
786-493
ACD (Acid Citrate Dextrose) Solution A (38mM citric acid, 107mM sodium citrate, 136mM dextrose), 25mL
Price: $195.34List Price: $217.04ACD (Acid Citrate Dextrose) Solution A andACD (Acid Citrate Dextrose)Solution B are anticoagulants for whole blood and also act as acidifying agents to platelet poor plasma. Features Solution A: 38mM citric acid, 107mM sodium citrate, 136mM dextrose -
786-858
ACD (Acid Citrate Dextrose) Solution A (38mM citric acid, 107mM sodium citrate, 136mM dextrose), 500mL
Price: $1,483.17List Price: $1,647.96ACD (Acid Citrate Dextrose) Solution A andACD (Acid Citrate Dextrose)Solution B are anticoagulants for whole blood and also act as acidifying agents to platelet poor plasma. Features Solution A: 38mM citric acid, 107mM sodium citrate, 136mM dextrose -
786-494
ACD (Acid Citrate Dextrose) Solution B (23mM citric acid, 65mM sodium citrate, 136mM dextrose), 25mL
Price: $177.88List Price: $197.64ACD (Acid Citrate Dextrose) Solution A andACD (Acid Citrate Dextrose)Solution B are anticoagulants for whole blood and also act as acidifying agents to platelet poor plasma. Features Solution A: 38mM citric acid, 107mM sodium citrate, 136mM dextrose -
4B7889Q
ANTICOAGULANT SOD. CITRATE SOL
Price: $649.35List Price: $721.50ANTICOAGULANT SOD. CITRATE SOL - (24/CS) -
C345267-50ml
Citrate-dextrose solution (ACD)
Price: $185.02List Price: $205.58Citrate-dextrose solution (ACD) is used for anticoagulation of whole blood and erythrocyte survival. Citrate-dextrose solution (ACD) is supplied as a 0.2μm-filtered, high quality solution.|Citrate-dextrose solution (ACD) is|supplied as 2 x 25 ml|, -
C485435-10×50ml
Citrate-phosphate-dextrose solution (C007B-104947)
Price: $941.23List Price: $1,045.81DescriptionCitrate-phosphate-dextrose solution (CPD) is an anticoagulant solution. It has 15% less citrate ion over citrate-phosphate-dextrose solution with adenine (ACD) and provides improved isotonicity, oxygen release function and posttransfusion -
C485435-50ml
Citrate-phosphate-dextrose solution (C007B-104948)
Price: $148.67List Price: $165.19DescriptionCitrate-phosphate-dextrose solution (CPD) is an anticoagulant solution. It has 15% less citrate ion over citrate-phosphate-dextrose solution with adenine (ACD) and provides improved isotonicity, oxygen release function and posttransfusion -
C7165-10X50ML
CITRATE-PHOSPHATE-DEXTROSE SOLUTION ASEPTICALLY FILLED (C005B-104254)
Price: $504.39List Price: $560.43Citrate-phosphate-dextrose solution (CPD) is an anticoagulant solution. It has 15% less citrate ion over citrate-phosphate-dextrose solution with adenine (ACD) and provides improved isotonicity, oxygen release function and posttransfusion viability -
C7165-50ML
CITRATE-PHOSPHATE-DEXTROSE SOLUTION ASEPTICALLY FILLED (C005B-104255)
Price: $84.03List Price: $93.37Citrate-phosphate-dextrose solution (CPD) is an anticoagulant solution. It has 15% less citrate ion over citrate-phosphate-dextrose solution with adenine (ACD) and provides improved isotonicity, oxygen release function and posttransfusion viability